Lite Strategy, Inc. (LITS) vs Serina Therapeutics, Inc. (SER)

Lite Strategy, Inc. and Serina Therapeutics, Inc. are both Biotechnology companies. Lite Strategy, Inc. and Serina Therapeutics, Inc. are of similar size ($54.4M and $51.0M). Lite Strategy, Inc. grew revenue faster over the last twelve months: 152.9% against −94.2%. Across the 15 metrics below, Lite Strategy, Inc. leads on 9 and Serina Therapeutics, Inc. on 6.

Valuation

Metric LITS SER Biotechnology median
P/E n/m n/m 7.88
P/S 0.49 189.20 11.47
P/B 0.90 1.83 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.42 95.00 10.73
Earnings yield (139.13%) (90.43%) (28.84%)
Free cash flow yield (20.24%) (61.91%) (23.03%)

Profitability

Metric LITS SER Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (159.26%) (306.22%) (57.72%)
Return on assets (154.82%) (136.00%) (49.22%)
Return on invested capital (73.66%) 0.00% 0.00%

Growth

Metric LITS SER Biotechnology median
Revenue growth (TTM) 152.90% (94.21%) 5.64%
EPS growth (last fiscal year) (189.51%) (26.49%) —
Revenue growth, 5-year CAGR 67.75% (18.48%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LITS SER Biotechnology median
Debt to equity 0.00 0.16 0.00
Current ratio 11.53 6.65 4.73
Net debt to EBITDA 1.05 0.00 0.96

Dividend

Metric LITS SER Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric LITS SER Biotechnology median
Market cap 51.04m 54.36m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack